Targeting costimulatory molecules to improve antitumor immunity.

Targeting costimulatory molecules to improve antitumor immunity.
复制标题

DOI:
10.1155/2012/926321
复制
发表时间:
2012
影响因子:
--
通讯作者:
Alesse E
Alesse E
中科院分区:
其他
文献类型:
--
作者:
Capece D;Verzella D;Fischietti M;Zazzeroni F;Alesse E

文献摘要

参考文献

被引文献

相似文献

T细胞的完全激活需要两个信号的伴随激活,肽/主要组织相容性复合体II与T细胞受体的接合和共刺激分子传递的额外信号。最具代表性的共刺激分子属于B7/CD 28和TNF/TNFR家族,在调节免疫应答和提高抗肿瘤免疫中起关键作用。不幸的是,肿瘤通常会产生免疫抑制微环境,其中T细胞反应因癌细胞表面缺乏共刺激分子而减弱。因此,靶向共刺激通路代表了一种有吸引力的治疗策略,以增强几种人类癌症的抗肿瘤免疫力。在这里,将描述靶向共刺激分子的最新治疗方法。
The full activation of T cells necessitates the concomitant activation of two signals, the engagement of T-cell receptor by peptide/major histocompatibility complex II and an additional signal delivered by costimulatory molecules. The best characterized costimulatory molecules belong to B7/CD28 and TNF/TNFR families and play crucial roles in the modulation of immune response and improvement of antitumor immunity. Unfortunately, tumors often generate an immunosuppressive microenvironment, where T-cell response is attenuated by the lack of costimulatory molecules on the surface of cancer cells. Thus, targeting costimulatory pathways represent an attractive therapeutic strategy to enhance the antitumor immunity in several human cancers. Here, latest therapeutic approaches targeting costimulatory molecules will be described.
DOI: 10.1038/sj.cgt.7700670
发表时间: 2004-03-01
影响因子: 6.4
作者:
Cheuk, ATC;Mufti, GJ;Guinn, BA
通讯作者: Guinn, BA
DOI: 10.1002/ijc.21098
发表时间: 2005-10-10
影响因子: 6.4
作者:
Cuadros, C;Dominguez, AL;Lustgarten, J
通讯作者: Lustgarten, J
DOI: 10.1073/pnas.0905139106
发表时间: 2009-12-01
影响因子: 11.1
作者:
Bogunovic, Dusan;O'Neill, David W.;Bhardwaj, Nina
通讯作者: Bhardwaj, Nina
DOI: 10.1186/1479-5876-7-93
发表时间: 2009-11-11
影响因子: 7.4
作者:
Carpenter, Erica L.;Mick, Rosemarie;Vonderheide, Robert H.
通讯作者: Vonderheide, Robert H.
DOI: 10.1158/1078-0432.ccr-07-4079
发表时间: 2008-05-15
影响因子: 11.5
作者:
Berger, Raanan;Rotem-Yehudar, Rinat;Nagler, Arnon
通讯作者: Nagler, Arnon